Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBOLA trial of luspatercept with epoetin alfa in lower-risk MDS without ring sideroblasts after ESA failure or ESA ineligibility
2024-515354-24-00Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of luspatercept and epoetin alfa in myelodysplastic syndrome (MDS) (3 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Optimal dose determination in Part A and Erythroid response in Part B. Planned start May 2022; status: authorised.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-515354-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515354-24-00.